GW Pharma gets FDA approval for Phase II/III trial of Epidiolex to treat Dravet Syndrome

British biopharmaceutical firm GW Pharmaceuticals has received confirmation from the US Food and Drug Administration (FDA) that its investigational new drug application (IND) is now open for Epidiolex in the treatment of Dravet dyndrome, also known a…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news